Literature DB >> 11923810

Blood pressure control and hormone replacement therapy in postmenopausal women at risk for coronary heart disease.

James A McCubbin1, Suzanne G Helfer, Fred S Switzer, Thomas M Price.   

Abstract

BACKGROUND: Coronary heart disease (CHD) in women is strongly associated with estrogen deprivation. For example, risk for CHD increases dramatically after menopause. However, the role of hormone replacement therapy (HRT) in CHD prevention currently is unresolved. To better understand CHD in women, the precise mechanisms by which estrogen affects circulatory function require clarification. Evidence suggests that exogenous estrogen may affect blood pressure (BP) control, but its interaction with other CHD risk factors has not been systematically characterized. The present study examines the role of mildly elevated resting BP, family history of CHD, and HRT on BP responses to stress in postmenopausal women.
METHODS: Postmenopausal women on long-term HRT were recruited along with a control group of postmenopausal women not on HRT. These women were divided into higher versus lower risk for CHD on the basis of resting BP and family history of CHD. BP control mechanisms were assessed before, during, and after a computer-controlled laboratory stressor.
RESULTS: Results indicate that women with elevated resting BP and positive family history of CHD have exaggerated BP reactivity to stress and that HRT inhibits this effect.
CONCLUSIONS: This study suggests that unmedicated postmenopausal women with mildly elevated resting BP and positive family history of CHD have altered BP control as indicated by exaggerated BP responses to stress. HRT eliminates the cumulative effect of resting BP and family history on BP reactivity, suggesting that the circulatory effects of estrogen replacement may operate, at least in part, through normalization of BP reactivity in higher-risk postmenopausal women.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11923810     DOI: 10.1067/mhj.2002.121262

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  7 in total

1.  Cognitive benefits of hormone therapy: cardiovascular factors and healthy-user bias.

Authors:  Whitney Wharton; Maritza Dowling; Christine M Khosropour; Cynthia Carlsson; Sanjay Asthana; Carey E Gleason
Journal:  Maturitas       Date:  2009-10-29       Impact factor: 4.342

Review 2.  Timing and duration of menopausal hormone treatment may affect cardiovascular outcomes.

Authors:  S Mitchell Harman; Eric Vittinghoff; Eliot A Brinton; Matthew J Budoff; Marcelle I Cedars; Rogerio A Lobo; George R Merriam; Virginia M Miller; Frederick Naftolin; Lubna Pal; Nanette Santoro; Hugh S Taylor; Dennis M Black
Journal:  Am J Med       Date:  2011-03       Impact factor: 4.965

3.  Activation of GPR30 attenuates diastolic dysfunction and left ventricle remodelling in oophorectomized mRen2.Lewis rats.

Authors:  Hao Wang; Jewell A Jessup; Marina S Lin; Clarissa Chagas; Sarah H Lindsey; Leanne Groban
Journal:  Cardiovasc Res       Date:  2012-02-10       Impact factor: 10.787

4.  Effects of estrogen and opioid blockade on blood pressure reactivity to stress in postmenopausal women.

Authors:  Allyssa J Allen; James A McCubbin; James P Loveless; Suzanne G Helfer
Journal:  J Behav Med       Date:  2012-11-09

5.  Premature and early menopause among US women with or at risk for HIV.

Authors:  Brooke W Bullington; Andrew Edmonds; Catalina Ramirez; Lisa Rahangdale; Genevieve Neal-Perry; Deborah Konkle-Parker; Deborah Jones Weiss; Caitlin Moran; Elizabeth Topper Golub; Helen Cejtin; Dominika Seidman; Seble Kassaye; Tracey E Wilson; Anjali Sharma; Adaora A Adimora; Andrea K Knittel
Journal:  Menopause       Date:  2022-06-01       Impact factor: 3.310

Review 6.  The influence of biological and lifestyle factors on circulating cell-free DNA in blood plasma.

Authors:  Nicole Laurencia Yuwono; Kristina Warton; Caroline Elizabeth Ford
Journal:  Elife       Date:  2021-11-09       Impact factor: 8.140

7.  Is the WHI relevant to HRT started in the perimenopause?

Authors:  S Mitchell Harman; Eliot A Brinton; Thomas Clarkson; Christopher B Heward; Harvey S Hecht; Richard H Karas; Debra R Judelson; Frederick Naftolin
Journal:  Endocrine       Date:  2004-08       Impact factor: 3.925

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.